STEP 2 Trial — Semaglutide in T2DM

Source: The Lancet (2021).

Key finding: 9.6% weight loss in T2DM.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
Weight Regain After Discontinuation of GLP-1 Receptor Agonists: A Systematic Review
Gastrointestinal Side Effects of Semaglutide in Indian Patients with Type 2 Diabetes
Indian Consensus Guidelines on Obesity Management Including GLP-1 Receptor Agonists

Take the Free Eligibility Assessment → · Compare All 18+ Brands